Nanwei Co., Ltd. 2025 Independent Director Work Report (Zhang Jun)

Jiangsu Nanfang Health Care Pharmaceutical Co., Ltd.

2025 Independent Directors’ Work Report

As an independent director of the fifth board of directors of Jiangsu Nanfang Weicai Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" and "Nanfang"), I strictly abide by the "Company Law", "Securities Law", "Administrative Measures for Independent Directors of Listed Companies", "Articles of Association", "Independent Director Work System" and other relevant regulations, faithfully perform the duties of an independent director, actively attend relevant meetings held by the company, carefully review various proposals and express opinions independently and objectively, give full play to the role of an independent director, work diligently and fulfill responsibilities, and safeguard the interests of all shareholders, especially small and medium-sized shareholders. The relevant work report on the performance of the duties of independent directors during the term of office in 2025 is now reported as follows:

1. Basic information of independent directors

I am Zhang Jun: male, born in March 1964, Chinese nationality, no right of residence abroad, member of the Communist Party of China, Doctor of Engineering. From July 1993 to April 1997, he served as an assistant professor in the Department of Polymers, Nanjing University of Chemical Technology; from May 1997 to April 2004, he served as an associate professor in the Department of Polymers, Nanjing University of Chemical Technology; from May 2004 to the present, he served as a professor in the School of Materials Science and Engineering, Nanjing University of Technology.

I have the independence required by the China Securities Regulatory Commission's "Measures for the Administration of Independent Directors of Listed Companies" and other laws and regulations, as well as the "Articles of Association" and "Independent Director Work System" and the qualifications to serve as an independent director of the company. I can ensure objective and independent professional judgment, and there are no circumstances that affect independence.

2. Annual performance of independent directors’ duties

(1) Attendance at board of directors and shareholders’ meetings

I have served as the fifth independent director of the company since December 25, 2025. During my term of office, the company held a total of one board of directors meeting and no shareholders' meeting. The attendance at the meeting is as follows:

Independence Attendance at the Board of Directors Attendance at the Shareholders' Meetings Directors should attend this year In person By communication By proxy Number of attendances at shareholder meetings Number of Board meetings Number of meetings Number of meetings Number of meetings

Zhang Jun 1 1 1 0 0

During the reporting period, I attended all board meetings held by the company. There was no absence or entrustment of other directors to attend the board meeting. The voting on various proposals strictly followed the principles of independence and professionalism. I carefully reviewed various board proposals, actively participated in discussions and put forward suggestions and opinions, and voted in favor of all matters reviewed by the board of directors without raising objections.

(2) Attendance at meetings of special committees of the board of directors

In accordance with the provisions and requirements of relevant laws, regulations, and systems, and based on my personal professional background, I serve as the convener of the Remuneration and Assessment Committee, the Audit Committee, and the Nomination Committee of the fifth session of the Board of Directors.

During the reporting period, the company held a total of 1 audit committee meeting and 1 nomination committee meeting. The specific attendance at the special committees of the board of directors is as follows:

Remuneration and Appraisal Committee Audit Committee Nomination Committee Number of meetings during the reporting period 0 1 1

Number of meetings to attend 0 1 1

Number of participations 0 1 1

(3) Exercising the powers of independent directors

During the reporting period, the company did not have any matters requiring independent directors to exercise special powers. During my tenure, I did not propose to convene a board of directors, did not propose to the board of directors to convene an extraordinary shareholders' meeting, did not publicly solicit shareholders' rights from shareholders, and did not independently hire an intermediary agency to audit, consult or verify specific matters of the company.

(4) Communication with internal audit institutions and accounting firms

In 2025, I actively communicated with the company's internal audit department and the annual audit accounting firm, and communicated and exchanged with the accounting firm on the annual audit plan, key points of attention and other matters.

(5) The company’s cooperation with independent directors

During the reporting period, the company's internal directors and senior managers attached great importance to communication with independent directors and actively shared the company's operating conditions and the progress of major events. Various meeting materials can be delivered timely and accurately, which provides convenience and efficiency for the convening and conduct of the company's board of directors meetings and the work of independent directors.

3. Matters of focus in annual performance of duties by independent directors

During the reporting period, we focused on the legality and compliance of the following matters in decision-making, execution and disclosure, and made independent and clear judgments. The details are as follows:

(1) Related transactions that should be disclosed

During the reporting period, the company had no related transactions that should be disclosed.

(2) Plans for listed companies and relevant parties to change or waive their commitments

During the reporting period, the company and relevant parties did not change or waive their commitments.

(3) Decisions made and measures taken by the board of directors of the acquired listed company regarding the acquisition

Not applicable.

(4) Disclosure of financial information in financial accounting reports and periodic reports, and internal control evaluation reports

In 2025, the company strictly complied with the requirements of relevant laws, regulations and normative documents such as the "Company Law", "Securities Law", "Measures for the Administration of Information Disclosure of Listed Companies", and as an independent director focused on the information disclosure of the company's regular reports. The relevant information disclosure work was timely, true, accurate and complete, in compliance with the requirements of the "Shanghai Stock Exchange Stock Listing Rules" and other relevant rules, and there were no major false records, misleading statements or major omissions. The financial information and internal control evaluation reports in the financial accounting reports and periodic reports disclosed by the company are in compliance with relevant laws, regulations and company systems. The decision-making procedures are legal and no major violations of laws and regulations have been found.

(5) Appointment or dismissal of financial officers of listed companies

During the reporting period, the company was not involved in relevant matters.

(6) Changes in accounting policies, accounting estimates or correction of major accounting errors due to reasons other than changes in accounting standards

During the reporting period, the company did not make any changes in accounting policies, accounting estimates or correction of major accounting errors due to reasons other than changes in accounting standards.

(7) Nominate or appoint or remove directors, hire or dismiss senior managers

During the reporting period, the company completed the general election work. On December 25, 2025, the company The first meeting of the fifth board of directors was held on the same day, and the "Proposal on the Election of the Chairman of the Company's Fifth Board of Directors", the "Proposal on the Appointment of the Company's General Manager", and the "Proposal on the Appointment of the Company's Secretary to the Board of Directors and Deputy General Manager" were reviewed and approved. The qualifications of independent directors elected by the company's board of directors and senior managers appointed by the company's board of directors are in compliance with relevant laws, regulations, normative documents and the relevant provisions of the Articles of Association. The review and voting procedures for election and appointment are legal and compliant, and there is no harm to the interests of the company and its shareholders, especially small and medium-sized shareholders.

(8) Matters related to equity incentives

During my tenure in 2025, no equity incentive-related matters occurred in the company.

4. Overall evaluation and suggestions

In 2025, I will be diligent and responsible, strictly follow relevant laws, regulations and company system documents, and adhere to the principles of objectivity, impartiality and independence, effectively perform my duties, participate in the company's decision-making on major matters, perform my duties prudently, faithfully and diligently, give full play to the role of an independent director, and safeguard the overall interests of the company and the legitimate rights and interests of shareholders, especially small and medium-sized shareholders.

In 2026, I will continue to exercise the rights of an independent director, fulfill the obligations of an independent director, play the role of an independent director, provide scientific and reasonable decision-making suggestions, and promote the high-quality development of the company in accordance with the provisions and requirements of laws, regulations, and the Articles of Association.

Independent Director: Zhang Jun

April 29, 2026